BACKGROUND: Cardiovascular disease (CVD) is increasing in HIV-infected patients. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population. We aimed to quantify the risk of CVD events associated with NT-proBNP at baseline in the Strategies for Management of Anti-Retroviral Therapy study. METHODS: In a nested case-control study, NT-proBNP was measured at baseline in 186 patients who experienced a CVD event over an average of 2.8 years of follow-up and in 329 matched controls. Odds ratios (ORs) associated with baseline levels of NT-proBNP for CVD were estimated using conditional logistic regression. RESULTS: At baseline median NT-proBNP [interquartile range (IQR)] was 48.1 (18.5, 112.9) pg/ml in patients who developed a CVD event and 25.7 (12.4, 50.2) pg/ml in controls. The unadjusted OR for the highest versus the lowest quartile was 3.7 [95% confidence interval (CI) 2.1-6.5, P < 0.0001]. After adjustment for baseline covariates and CVD risk factors, OR was 2.8 (95% CI 1.4-5.6, P = 0.003); with additional adjustment for IL-6, high-sensitivity C-reactive protein and D-dimer, OR was 2.3 (95% CI 1.1-4.9, P = 0.02). CONCLUSIONS: Higher levels of NT-proBNP are associated with increased risk of CVD in HIV patients after considering established CVD risk factors and markers for inflammation and thrombosis.
BACKGROUND: Cardiovascular disease (CVD) is increasing in HIV-infected patients. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population. We aimed to quantify the risk of CVD events associated with NT-proBNP at baseline in the Strategies for Management of Anti-Retroviral Therapy study. METHODS: In a nested case-control study, NT-proBNP was measured at baseline in 186 patients who experienced a CVD event over an average of 2.8 years of follow-up and in 329 matched controls. Odds ratios (ORs) associated with baseline levels of NT-proBNP for CVD were estimated using conditional logistic regression. RESULTS: At baseline median NT-proBNP [interquartile range (IQR)] was 48.1 (18.5, 112.9) pg/ml in patients who developed a CVD event and 25.7 (12.4, 50.2) pg/ml in controls. The unadjusted OR for the highest versus the lowest quartile was 3.7 [95% confidence interval (CI) 2.1-6.5, P < 0.0001]. After adjustment for baseline covariates and CVD risk factors, OR was 2.8 (95% CI 1.4-5.6, P = 0.003); with additional adjustment for IL-6, high-sensitivity C-reactive protein and D-dimer, OR was 2.3 (95% CI 1.1-4.9, P = 0.02). CONCLUSIONS: Higher levels of NT-proBNP are associated with increased risk of CVD in HIV patients after considering established CVD risk factors and markers for inflammation and thrombosis.
Authors: R Marcucci; A M Gori; F Giannotti; M Baldi; V Verdiani; S Del Pace; C Nozzoli; R Abbate Journal: J Thromb Haemost Date: 2006-05 Impact factor: 5.824
Authors: W M El-Sadr; B Grund; J Neuhaus; A Babiker; C J Cohen; J Darbyshire; S Emery; J D Lundgren; A Phillips; J D Neaton Journal: Ann Intern Med Date: 2008-09-02 Impact factor: 25.391
Authors: Niels Obel; Henrik F Thomsen; Gitte Kronborg; Carsten S Larsen; Per R Hildebrandt; Henrik T Sørensen; Jan Gerstoft Journal: Clin Infect Dis Date: 2007-05-10 Impact factor: 9.079
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Andrew N Phillips; Andrew Carr; Jacquie Neuhaus; Fehmida Visnegarwala; Ronald Prineas; William J Burman; Ian Williams; Fraser Drummond; Daniel Duprez; Waldo H Belloso; Frank-Detlef Goebel; Birgit Grund; Angelos Hatzakis; Jose Vera; Jens D Lundgren Journal: Antivir Ther Date: 2008
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Caitlin A Murphy; Kathleen V Fitch; Meghan Feldpausch; Patrick Maehler; Kimberly Wong; Martin Torriani; Gail K Adler; Steven K Grinspoon; Suman Srinivasa Journal: J Clin Endocrinol Metab Date: 2018-04-01 Impact factor: 5.958
Authors: Sahera Dirajlal-Fargo; Bruce Kinley; Ying Jiang; Chris T Longenecker; Corrilynn O Hileman; Sara Debanne; Grace A McComsey Journal: AIDS Date: 2015-01-28 Impact factor: 4.177
Authors: Raza M Alvi; Markella V Zanni; Anne M Neilan; Malek Z O Hassan; Noor Tariq; Lili Zhang; Maryam Afshar; Dahlia Banerji; Connor P Mulligan; Adam Rokicki; Magid Awadalla; James L Januzzi; Tomas G Neilan Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Eric A Secemsky; Rebecca Scherzer; Elaine Nitta; Alan H B Wu; David C Lange; Steven G Deeks; Jeffrey N Martin; James Snider; Peter Ganz; Priscilla Y Hsue Journal: JACC Heart Fail Date: 2015-07-08 Impact factor: 12.035
Authors: Javed Butler; Andreas P Kalogeropoulos; Kevin J Anstrom; Priscilla Y Hsue; Raymond J Kim; Rebecca Scherzer; Sanjiv J Shah; Svati H Shah; Eric J Velazquez; Adrian F Hernandez; Patrice Desvigne-Nickens; Eugene Braunwald Journal: J Card Fail Date: 2018-03-02 Impact factor: 5.712